Ni Yicheng, Wang Huaijun, Chen Feng, Li Junjie, DeKeyzer Frederik, Feng Yuanbo, Yu Jie, Bosmans Hilde, Marchal Guy
Section of Radiology, Department of Medical Diagnostic Sciences, Biomedical Sciences Group, University of Leuven, Belgium.
Methods. 2009 Jun;48(2):125-38. doi: 10.1016/j.ymeth.2009.03.014. Epub 2009 Mar 26.
Despite the widespread use of various imaging modalities in clinical and experimental oncology without or with combined application of commercially available nonspecific contrast agents (CAs), development of tissue- or organ- or disease-specific CAs has been a continuing effort for pursuing ever-improved sensitivity, specificity, and applicability. This is particularly true with magnetic resonance imaging (MRI) due to its intrinsic superb spatial/temporal/contrast resolutions and adequate detectability for tiny amount of substances. In this context, research using small animal tumor models has played an indispensible role in preclinical exploration of tissue specific CAs. Emphasizing more on methodological and practical aspects, this article aims to share our cumulated experiences on how to create tumor models for evaluation and development of new tissue specific MRI CAs and how to apply such models in imaging-based research studies. With the results that are repeatedly confirmed by later clinical applications in cancer patients, some of our early preclinical studies have contributed to the designs of subsequent clinical trials on the new CAs, some studies have predicted new utilities of these CAs; and other studies have led to the discoveries of new tissue- or disease-specific CAs with novel diagnostic or even therapeutic potentials. Among commonly adopted tumor models, the chemically induced and surgically implanted nodules in the liver prove very useful to simulate primary and metastatic intrahepatic tumors, respectively in clinical patients. The methods to create tumor models have eased procedures and yielded high success rates. The specific properties of the new CAs could be outshined by intraindividual comparison to the commercial CAs as nonspecific controls. Meticulous imaging-microangiography-histology matching techniques guaranteed colocalization of the lesion on in vivo MRI and postmortem tissue specimen, hence correct imaging interpretation and longstanding conclusions. As exemplified in the real study cases, the present experimental set-up proves applicable in small animals for imaging-based oncological investigations, and may provide a platform for the currently booming molecular imaging in a multimodality environment.
尽管在临床和实验肿瘤学中广泛使用了各种成像方式,无论是否联合应用市售的非特异性造影剂(CAs),开发组织、器官或疾病特异性的CAs一直是人们不断努力的方向,旨在追求更高的敏感性、特异性和适用性。对于磁共振成像(MRI)而言尤其如此,因为它具有出色的空间/时间/对比度分辨率以及对微量物质的足够检测能力。在此背景下,使用小动物肿瘤模型的研究在组织特异性CAs的临床前探索中发挥了不可或缺的作用。本文更侧重于方法和实践方面,旨在分享我们在如何创建肿瘤模型以评估和开发新型组织特异性MRI CAs以及如何将此类模型应用于基于成像的研究方面积累的经验。我们的一些早期临床前研究结果已被后来在癌症患者中的临床应用反复证实,这些研究为后续关于新型CAs的临床试验设计做出了贡献,一些研究预测了这些CAs的新用途;其他研究则导致发现了具有新诊断甚至治疗潜力的新型组织或疾病特异性CAs。在常用的肿瘤模型中,化学诱导的和手术植入的肝脏结节分别被证明对模拟临床患者的原发性和转移性肝内肿瘤非常有用。创建肿瘤模型的方法简化了操作程序并产生了高成功率。与作为非特异性对照的商用CAs进行个体内比较时,新型CAs的特异性特性可能会更加突出。细致的成像 - 微血管造影 - 组织学匹配技术确保了体内MRI上的病变与死后组织标本的共定位,从而实现正确的成像解读和长期结论。正如实际研究案例所示,目前的实验设置证明适用于小动物的基于成像的肿瘤学研究,并可能为当前在多模态环境中蓬勃发展的分子成像提供一个平台。